What do systematic reviews say?

10 questions · 10 findings · 4 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 60%GRADE not reported 4 · 40%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

GROUP PSYCHOSOCIAL THERAPY (GPT) + TAU vs TAU

Adverse events: Not reported · Adolescents with psychosis

The review found no eligible studies for this question.

1 finding from 1 review

Psychological interventions for psychosis in adolescents 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

STRUCTURAL GROUP THERAPY (SGT) + TAU vs HANDICRAFT GROUP (HC) + TAU (all short‐term)

Adverse events: Not reported · Adolescents with psychosis

The review found no eligible studies for this question.

1 finding from 1 review

Psychological interventions for psychosis in adolescents 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PSYCHOEDUCATIONAL (PE) + MULTIFAMILY TREATMENT (MFT) vs NONSTRUCTURED GROUP THERAPY (NSGT, all long‐term)

Adverse events: Not reported · Adolescents with psychosis

The review found no eligible studies for this question.

1 finding from 1 review

Psychological interventions for psychosis in adolescents 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

DOPAMINERGIC DRUGS vs placebo

Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

DOPAMINERGIC DRUGS vs other drugs

Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

NORADRENERGIC DRUGS vs placebo

Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

NORADRENERGIC DRUGS vs DOPAMINERGIC DRUGS

Adverse events ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia

1 finding from 1 review

Non‐antipsychotic catecholaminergic drugs for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

PERPHENAZINE vs placebo

Adverse events: death ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Perphenazine for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

PERPHENAZINE vs placebo

Adverse events: serious adverse events ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Perphenazine for schizophrenia 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Adverse events: related to movement disorder, weight gain, prolactin levels and glucose metabolism ‐ medium/long term ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found